Technology | April 17, 2014

Medtronic CRT Devices Now Approved to Treat Patients With AV Block and Reduced Heart Function

Landmark BLOCK HF trial demonstrates clinical benefits of biventricular pacing in new patient population

April 17, 2014 — Medtronic announced the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization therapy-pacemakers and -defibrillators (CRT-P and CRT-D). Medtronic CRT devices are now approved to treat patients with atrioventricular (AV) block and left ventricular (LV) systolic dysfunction, reducing heart failure hospitalizations and mortality, and improving cardiac function in these patients.

The expanded indication allows patients designated as New York Heart Association (NYHA) Class I, II and III heart failure with AV block that are expected to require a high percentage of ventricular pacing, and who have an ejection fraction (EF) less than or equal to 50 percent, to receive BiV pacing via Medtronic CRT devices.

The FDA's approval was based on the landmark BLOCK HF clinical trial, which demonstrated significant clinical advantages of BiV pacing compared with traditional right ventricular (RV) pacing in this patient population, including a 27 percent relative risk reduction in the composite study endpoint of heart size, heart failure hospitalizations and mortality.

"For patients with AV block and LV dysfunction, traditional RV pacing may escalate the progression of heart failure," said Anne B. Curtis, M.D., BLOCK HF lead investigator and chair of the department of medicine at the University at Buffalo School of Medicine and Biomedical Sciences, Buffalo, N.Y. "The BLOCK HF clinical trial provided strong clinical evidence validating the safety and efficacy of BiV pacing in this patient population."

More than 1 million Americans have AV block, which reduces the heart's ability to properly function by blocking the electrical signals between its top and bottom chambers. Symptoms of the condition are fainting, dizziness and shortness of breath. A debilitating and often deadly disease, heart failure will cost the United States an estimated $32 billion in 2013, with projections showing a 120 percent increase in cost by 2030 for a total of $70 billion.

"Medtronic is pleased with the FDA's decision to expand the use of BiV pacing with Medtronic CRT-P and CRT-D devices in this new patient population," said David Steinhaus, M.D., vice president and general manager, heart failure, and medical director for the cardiac rhythm disease management business at Medtronic. "We have more than a decade of evidence showing that CRT improves quality of life for heart failure patients, and we now have also demonstrated improved outcomes for AV block patients with these devices."

For more information: www.medtronic.com

Related Content

Abbott Announces MR-Conditional Labeling for Quadra Assura CRT-D and Fortify Assura ICD
Technology | Cardiac Resynchronization Therapy Devices (CRT) | January 03, 2018
Abbott announced U.S. Food and Drug Administration (FDA) approval for magnetic resonance (MR)-conditional labeling for...
Biotronik Announces U.S. Launch of Edora HF-T QP CRT Pacemaker
Technology | Cardiac Resynchronization Therapy Devices (CRT) | August 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and commercial availability of Edora HF-T QP, an...
Biotronik Launches DX Technology for U.S. Heart Failure Patients
News | Cardiac Resynchronization Therapy Devices (CRT) | July 21, 2017
Biotronik announced U.S. Food and Drug Administration (FDA) approval and availability of the Intica DX and Intica...
Videos | Cardiac Resynchronization Therapy Devices (CRT) | May 23, 2017
This video, provided by ERB, demonstrates the function and implantation of the WiSE CRT (Wireless Stimulation Endocar
Biotronik Announces FDA Approval of MultiPole Pacing
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 11, 2017
May 11, 2017 — Biotronik announced U.S.
Biotronik Launches First FDA-Approved CRM Devices with MRI AutoDetect Technology
Technology | Cardiac Resynchronization Therapy Devices (CRT) | May 10, 2017
Biotronik announced the availability of the first U.S. Food and Drug Administration (FDA)-approved cardiac rhythm...
NICE Recommends Boston Scientific CRT-Ds With EnduraLife Battery Technology for Heart Failure Treatment
News | Cardiac Resynchronization Therapy Devices (CRT) | April 14, 2017
The National Institute for Health and Care Excellence (NICE) recently issued medical technology guidance recommending...
Biotronik, Edora series, pacemakers, CRT-Ps
Technology | Cardiac Resynchronization Therapy Devices (CRT) | March 23, 2017
March 23, 2017 — Biotronik announced the European launch of the Edora series, its smallest series of...
Overlay Init